JSI-124 Activates JNK Pathway in B Leukemic Cells
Author Information
Author(s): Ishdorj Ganchimeg, Johnston James B, Gibson Spencer B
Primary Institution: Manitoba Institute of Cell Biology, Winnipeg, MB, Canada
Hypothesis
JSI-124 activates the JNK signaling pathway independent of apoptosis and cell cycle arrest.
Conclusion
JSI-124 activates the JNK signaling pathway, leading to increased VEGF expression without inducing apoptosis or cell cycle arrest.
Supporting Evidence
- JSI-124 activates c-Jun N-terminal kinase (JNK) in B leukemic cell lines.
- Inhibition of JNK did not affect apoptosis or cell cycle arrest induced by JSI-124.
- JSI-124 treatment increased VEGF expression at both mRNA and protein levels.
Takeaway
JSI-124 is a drug that helps certain cancer cells grow by turning on a pathway that makes a substance called VEGF, which helps blood vessels grow.
Methodology
B leukemic cell lines were treated with JSI-124, and various assays were performed to measure apoptosis, cell cycle, and protein expression.
Limitations
The study does not address the long-term effects of JSI-124 treatment or its efficacy in vivo.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website